CAMBRIDGE, Mass., Feb. 26, 2020 /PRNewswire/ -- Leap Therapeutics,
Inc. (Nasdaq: LPTX), a biotechnology company focused on developing
targeted and immuno-oncology therapeutics, today announced that
Christopher K. Mirabelli, Ph.D.,
Chairman, President and Chief Executive Officer, Douglas E. Onsi, Chief Financial Officer, and
Cynthia Sirard, MD, Vice President,
Clinical Research & Development, will present a corporate
overview at the Cowen 40th Annual Health Care
Conference, being held in Boston
on March 2-4, 2020. The presentation
will be followed by a 30-minute breakout session.
Leap Presentation and Breakout Session Details:
Cowen 40th Annual Health Care Conference
Date: Wednesday, March 4, 2020
Presentation Time: 8:40 a.m. Eastern
Time
Breakout Session Time: 9:20 a.m. Eastern
Time
The presentation will be webcast live and may be accessed on the
Investors page of the company's website at
https://investors.leaptx.com/, where a replay of the event will
also be available for a limited time.
About Leap Therapeutics
Leap Therapeutics
(Nasdaq:LPTX) is focused on developing targeted and immuno-oncology
therapeutics. Leap's most advanced clinical candidate, DKN-01, is a
humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01
is in clinical trials in patients with esophagogastric,
hepatobiliary, gynecologic, and prostate cancers. Leap has formed a
partnership with BeiGene, Ltd. for the rights to develop DKN-01 in
Asia (excluding Japan), Australia, and New
Zealand. For more information about Leap Therapeutics, visit
http://www.leaptx.com or our public filings with the SEC that are
available via EDGAR at http://www.sec.gov or via
https://investors.leaptx.com/.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934 and the Private
Securities Litigation Reform Act of 1995, which involve risks and
uncertainties. These statements include statements regarding
expectations with respect to the development and advancement of
DKN-01, including the initiation, timing and design of future
studies, enrollment in future studies, potential for the receipt of
future option exercise, milestones or royalty payments from
BeiGene, and other future expectations, plans and prospects.
Although Leap believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made,
forward-looking statements are subject to known and unknown risks,
uncertainties and other factors that could cause actual results to
differ materially from our expectations. Such risks and
uncertainties include, but are not limited to: the accuracy of our
estimates regarding expenses, future revenues, capital requirements
and needs for financing; the outcome, cost, and timing of our
product development activities and clinical trials; the uncertain
clinical development process, including the risk that clinical
trials may not have an effective design or generate positive
results; our ability to obtain and maintain regulatory approval of
our drug product candidates; the size and growth potential of the
markets for our drug product candidates; our ability to continue
obtaining and maintaining intellectual property protection for our
drug product candidates; and other risks. Detailed information
regarding factors that may cause actual results to differ
materially will be included in Leap Therapeutics' periodic filings
with the SEC, including Leap's Annual Report on Form 10-K for the
fiscal year ended December 31, 2018,
as filed with the SEC on April 1,
2019, and Leap's Quarterly Reports on Form 10-Q. Any
forward-looking statements contained in this release speak only as
of its date. We undertake no obligation to update any
forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the
occurrence of unanticipated events.
CONTACT:
Douglas E. Onsi
Chief Financial Officer
Leap Therapeutics, Inc.
617-714-0360
donsi@leaptx.com
Heather Savelle
Investor Relations
Argot Partners
212-600-1902
heather@argotpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/leap-therapeutics-to-present-at-cowen-40th-annual-health-care-conference-301011310.html
SOURCE Leap Therapeutics, Inc.